CompletedPhase 2NCT00479934
Efficacy and Safety of Imatinib in Scleroderma
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Bordeaux
- Principal Investigator
- Alain TAIEB, Pr.University Hospital, Bordeaux, France
- Intervention
- imatinib mesylate(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2010
Study locations (12)
- Service de Dermatologie et services de médecine interne et vasculaire - Hôpital St André - CHU de Bordeaux, Bordeaux, France
- Service de Rhumatologie, Hôpital Pellegrin-Tondu CHU de Bordeaux, Bordeaux, France
- Service de Dermatologie - CHG Libourne, Libourne, France
- Service de dermatologie - CHU de Limoges, Limoges, France
- Service de Médecin interne - Hôpital central, Nancy, France
- Service de Médecine interne - Hôpital Saint Louis, Paris, France
- Service de Dermatologie - service de médecine interne et vasculaire - hopital haut Lévêque - av.de magellan, Pessac, France
- Service de Dermatologie - CHG Périgueux, Périgueux, France
- Service de Rhumatologie - CHU de Strasbourg, Strasbourg, France
- Service de Dermatologie - CHU de Toulouse - Hopital Purpan, Toulouse, France
- Service de Médecine interne - CHU de Tours, Tours, France
- Néphrologie et Médecine interne - CH de Valenciennes, Valenciennes, France
Collaborators
Ministry of Health, France · Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00479934 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University